Skip to main content
. 2024 Feb 26;12(3):519. doi: 10.3390/biomedicines12030519

Figure 3.

Figure 3

Evolution of research directions in biomarker analysis with the new SOC of EVP in mUC. Abbreviations: DDR: DNA damage response and repair; EVP: enfortumab vedotin + pembrolizumab; EV (P): enfortumab vedotin with or without pembrolizumab; FGFR: fibroblast growth factor receptor; ICIs: immune checkpoint inhibitor; MRD: molecular residual disease; MSS: microsatellite status; PD-L1: programmed death ligand 1; TMB: tumor mutational burden; TME: tumor microenvironment.